Business Daily Media

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

  • Written by PR Newswire

HONG KONG, July 13, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia. AK117 resulted in no dose-limiting toxicity (DLT) and no anemia of clinical...

Hire a Removalist: Your Guide To The Right Movers

Hiring removalists for your move is the best way to ensure this stressful experience runs smoothly. With their help and expertise, you can rest as...

Property

Here are Mistakes You Need to Avoid When Buying Your First Piece of Land

Buying land is a great investment. However, most first-time buyers often think that buying a house is easy, and they end up making mistakes. It’s i...

Property

5 easy ways to be a more effective leader

A manager I used to work with defined leadership as “achieving results through people”.  He was an excellent leader.  He clearly set the strategy fo...

Business Training

Power BI Examples Reports

In this article we will be looking at some Power BI Examples Reports. These reports are great for learning how to use Power BI effectively. In this...

Business Training

LOCALLY-LOVED, REGIONAL PUB SELLS FOR RECORD YIELD

A regional investor has purchased the Young Hotel, located at 89 Lynch Street, Young – testimony to the  continued demand for regional investments. ...

Property

Accelerating Business Growth: A Comprehensive Review of Strategies and Tactics

If you are a business owner, you know that growth is essential for success. However, achieving business growth is not always a straightforward process...

Business Training